Markets:

Overview

News

Currencies

International

Treasuries

Fate Therapeutics, Inc. - Common Stock (NQ:FATE)

1.080 +0.070 (+6.93%)

Streaming Delayed Price Updated: 2:09 PM EST, Jan 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Fate Therapeutics, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Fate Therapeutics Features Multiple Novel Approaches to Eliminate Conditioning Chemotherapy for Off-the-shelf, iPSC-derived Cell Therapies at 2022 ASH Annual Meeting

December 13, 2022

Next-generation Engineering Strategies Designed to Resist Host Immune Cell Rejection Show Enhanced Functionality and Persistence of iPSC-derived Cells in Preclinical Allogeneic Models

From Fate Therapeutics, Inc.

Via GlobeNewswire

RH, HUYA, Bilibili And Some Other Big Stocks Moving Lower On Monday ↗

December 12, 2022

U.S. stocks traded higher, with the Dow Jones jumping more than 200 points on Monday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Fate Therapeutics Initiated With Hold Rating - Read Why ↗

July 28, 2022

Via Benzinga

Why Harpoon Therapeutics Shares Are Trading Higher By 97%? Here Are 53 Stocks Moving In Monday's Mid-Day Session ↗

December 12, 2022

Gainers HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) shares jumped 165.7% to $1.4350 after jumping around 118% on Friday. HTG Molecular Diagnostics, last month, posted a Q3 loss of $0.41 per share.

Via Benzinga

GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022

December 12, 2022

From GT Biopharma, Inc.

Via GlobeNewswire

Fate Therapeutics Highlights iPSC-derived, Off-the-shelf CAR NK Cell Programs for Multiple Myeloma at 2022 ASH Annual Meeting

December 10, 2022

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Announces Clinical Safety and Activity Data of First-ever iPSC-derived CAR T-cell Therapy at 2022 ASH Annual Meeting

December 10, 2022

From Fate Therapeutics, Inc.

Via GlobeNewswire

What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers

December 06, 2022

Since Robert Hooke discovered cells in 1665 and Theodor Schwann proposed the classical cell theory in 1839, the cell therapy industry has grown by leaps and bounds.

Via TheNewswire.com

What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers

December 06, 2022

By Ernest Dela Aglanu, Benzinga

Via News Direct

Fate Therapeutics Announces Exercise by ONO Pharmaceutical of Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors

November 07, 2022

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics to Present at Upcoming Investor Conferences

November 04, 2022

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Operational Progress

November 03, 2022

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the 2022 ASH Annual Meeting

November 03, 2022

From Fate Therapeutics, Inc.

Via GlobeNewswire

Preview: Fate Therapeutics's Earnings ↗

November 02, 2022

Fate Therapeutics (NASDAQ:FATE) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that Fate...

Via Benzinga

What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers ↗

October 25, 2022

Since Robert Hooke discovered cells in 1665 and Theodor Schwann proposed the classical cell theory in 1839, the cell therapy industry has grown by leaps and bounds.

Via Benzinga

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2022 Financial Results

October 24, 2022

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the Society for Immunotherapy of Cancer 37th Annual Meeting

October 05, 2022

From Fate Therapeutics, Inc.

Via GlobeNewswire

Tesla, Meta, NVIDIA And Other Big Losers From Tuesday ↗

September 14, 2022

U.S. stocks closed sharply lower with the Nasdaq Composite dipping more than 5% on Tuesday. Here is the list of some big stocks moving lower in the previous session.

Via Benzinga

Apple, Amazon, HP And Other Big Losers From Friday ↗

August 29, 2022

U.S. stocks closed sharply lower with the Dow Jones tumbling more than 1,000 points on Friday. Here is the list of some big stocks moving lower in the previous session.

Via Benzinga

This Healthcare Stock Is Trading Lower By 29%: Here Are 29 Stocks Moving Premarket ↗

August 18, 2022

Gainers

Via Benzinga

Why Everbridge Jumped Over 17%; Here Are 90 Biggest Movers From Friday ↗

August 29, 2022

Gainers Micro Focus International plc (NYSE: MFGP) shares surged 92% to close at $6.01 on Friday after the company reached an agreement with OpenText to be acquired for $6 billion.

Via Benzinga

7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher ↗

August 17, 2022

These monkeypox stocks could be among the best choices to buy in August. Each can make great investments as government responses ramp up.

Via InvestorPlace

The 5 Top Stocks Cathie Wood Is Buying Now ↗

August 15, 2022

Cathie Wood's ETFs have performed well following the release of July's CPI report. Recent Cathie Wood stocks include NVTA, TDOC and RBLX.

Via InvestorPlace

Cathie Wood Is Buying Up Red-Hot Fate Therapeutics (FATE) Stock ↗

August 12, 2022

FATE stock is in focus after Cathie Wood's Ark Invest purchased over 600,000 shares yesterday. This was Ark's first purchase since February.

Via InvestorPlace

Cathie Wood Scoops Up Over $20M Worth Of Fate Therapeutics Shares, Dumps More Twitter Stock ↗

August 12, 2022

Cathie Wood-led Ark Investment Management has bought 628,060 shares of clinical-stage biopharmaceutical company Fate Therapeutics Inc. (NASDAQ: FATE) through two of the firm’s exchange-traded funds...

Via Benzinga

This Technology Stock Jumped 55% Following Q2 Results; Here Are 96 Biggest Movers From Yesterday ↗

August 17, 2022

Gainers Eargo, Inc. (NASDAQ: EAR) jumped 77.2% to close at $2.02. The FDA finalized rule enabling access to over-the-counter hearing aids.

Via Benzinga

7 Small-Cap Stocks to Buy Before the Bull Market Returns ↗

August 07, 2022

These small-cap stocks to buy before the bull market returns have underperformed the market, but have immense potential for future gains.

Via InvestorPlace

10 Health Care Stocks With Whale Alerts In Today's Session ↗

August 04, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial ↗

August 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 28, 2022 ↗

July 28, 2022

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.